28199964|t|Blockade of Rho-associated protein kinase (ROCK) inhibits the contractility and invasion potential of cancer stem like cells
28199964|a|Recent studies have implicated the roles of cancer stem like cells (CSCs) in cancer metastasis. However, very limited knowledge exists at the molecular and cellular level to target CSCs for prevention of cancer metastasis. In this study, we examined the roles of contractile dynamics of CSCs in cell invasion and delineated the underlying molecular mechanisms of their distinct cell invasion potential. Using de-adhesion assay and atomic force microscopy, we show that CSCs derived from melanoma and breast cancer cell lines exhibit increased contractility compared to non-CSCs across all tumor types. In addition, CSCs possess increased ECM remodeling capacity as quantified by collagen degradation assay. More importantly, pharmacological blockade of Rho-associated protein kinase completely abolished the contractility and collagen degradation capacity of both CSCs and non-CSCs. In conclusion, our study demonstrates the importance of cell contractility in regulating invasiveness of CSCs and suggests that pharmacological targeting of ROCK pathway represents a novel strategy for targeting both CSCs and bulk population for the treatment of cancer metastasis.
28199964	12	41	Rho-associated protein kinase	T103	UMLS:C0389995
28199964	43	47	ROCK	T103	UMLS:C0389995
28199964	62	75	contractility	T038	UMLS:C0007613
28199964	80	88	invasion	T038	UMLS:C2699153
28199964	89	98	potential	T033	UMLS:C0243095
28199964	102	124	cancer stem like cells	T017	UMLS:C1956422
28199964	169	191	cancer stem like cells	T017	UMLS:C1956422
28199964	193	197	CSCs	T017	UMLS:C1956422
28199964	202	219	cancer metastasis	T038	UMLS:C2939420
28199964	306	310	CSCs	T017	UMLS:C1956422
28199964	329	346	cancer metastasis	T038	UMLS:C2939420
28199964	412	416	CSCs	T017	UMLS:C1956422
28199964	420	433	cell invasion	T038	UMLS:C2699153
28199964	464	484	molecular mechanisms	T038	UMLS:C3537153
28199964	503	516	cell invasion	T038	UMLS:C2699153
28199964	517	526	potential	T033	UMLS:C0243095
28199964	534	551	de-adhesion assay	T058	UMLS:C0022885
28199964	556	579	atomic force microscopy	T058	UMLS:C0242849
28199964	594	598	CSCs	T017	UMLS:C1956422
28199964	612	620	melanoma	T017	UMLS:C1513095
28199964	625	649	breast cancer cell lines	T017	UMLS:C1512505
28199964	668	681	contractility	T038	UMLS:C0007613
28199964	694	702	non-CSCs	T017	UMLS:C0038250
28199964	740	744	CSCs	T017	UMLS:C1956422
28199964	763	766	ECM	T017	UMLS:C0015350
28199964	804	812	collagen	T103	UMLS:C0009325
28199964	813	830	degradation assay	T058	UMLS:C0022885
28199964	878	907	Rho-associated protein kinase	T103	UMLS:C0389995
28199964	933	946	contractility	T038	UMLS:C0007613
28199964	951	980	collagen degradation capacity	T038	UMLS:C1157968
28199964	989	993	CSCs	T017	UMLS:C1956422
28199964	998	1006	non-CSCs	T017	UMLS:C0038250
28199964	1069	1082	contractility	T038	UMLS:C0007613
28199964	1113	1117	CSCs	T017	UMLS:C1956422
28199964	1136	1161	pharmacological targeting	T038	UMLS:C0599894
28199964	1165	1169	ROCK	T103	UMLS:C0389995
28199964	1170	1177	pathway	T038	UMLS:C1148560
28199964	1210	1219	targeting	T038	UMLS:C0599894
28199964	1225	1229	CSCs	T017	UMLS:C1956422
28199964	1258	1267	treatment	T058	UMLS:C0087111
28199964	1271	1288	cancer metastasis	T038	UMLS:C2939420